Result of AGM and Directorate Changes

RNS Number : 5135U

Advanced Oncotherapy PLC

29 July 2020

 

29 July 2020

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Result of AGM and Directorate Changes

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at the Annual General Meeting held earlier today, all resolutions were passed on a poll. The results of the proxy voting for the AGM are set out below:

Resolution	Total votes For1	% of votes cast2	Total Votes Against	% of votes cast2	Votes Withheld3
1. To receive the audited financial statements and the Auditor's and Directors' reports for the year ended 31st December 2019.	172,734,768	99.95	90,000	0.05	3,013
2. To re-appoint Michael Bradfield as a Director of the Company.	172,734,286	99.95	93,330	0.05	165
3. To re-appoint Hans von Celsing as a Director of the Company.	172,734,286	99.95	93,330	0.05	165
4. To re-appoint Prof. Steve Myers as a Director of the Company.	172,824,286	99.99	830	0.01	2,665
5. To re-appoint Dr Nick Plowman as a Director of the Company.	172,824,286	99.99	830	0.01	2,665
6. To re-appoint Nicolas Serandour as a Director of the Company.	172,824,286	99.99	830	0.01	2,665
7. To re-appoint Dr Michael Sinclair as a Director of the Company.	172,826,786	99.99	995	0.01	0
8. To re-appoint Dr Enrico Vanni as a Director of the Company.	172,736,786	99.95	90,830	0.05	165
9. To re-appoint Renhua Zhang as a Director of the Company.	172,823,286	99.99	1,830	0.01	2,665
10. To re-appoint RPG Crouch Chapman LLP as Auditors of the Company to hold office until the conclusion of the next AGM at which accounts are laid before the Company	172,826,951	100.00	0	0.00	830
11. To authorise the Directors to determine the remuneration of the Auditors.	172,823,451	99.90	3,500	0.01	830
12. Authority to allot shares	172,822,517	99.99	5,264	0.01	0
13. Authority to disapply pre-emption rights	172,703,050	99.93	124,566	0.07	165

Notes

1.  Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution

2.  Percentage of votes cast excludes Votes Withheld

3.  Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution

Directorate Changes  

As announced on 8 June 2020, Mr Gabriel Urwitz, Mr Peter Sjöstrand, Mr Chunlin "Allen" Han and Dr Yuelong Huang (all Non-Executive Directors of the Company) did not seek re-election at the Company's AGM. Accordingly, these directors have now stepped down from the Board with immediate effect and consequently the size of the Board has decreased from 12 to 8 people.

- ENDS -

Advanced Oncotherapy plc	www.avoplc.com
Dr. Michael Sinclair, Executive Chairman	Tel: [phone]
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad & Broker)
Nick Athanas / Liz Kirchner (Corporate Finance) Amrit Nahal / Matt Butlin (Sales & Broking)	Tel: [phone]
FTI Consulting (Financial PR & IR)	[e-mail]
Simon Conway / Rob Winder	Tel: [phone]

Notes for Editors

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

RAGKZGZNFLGGGZM